

TABLE OF CONTENTS

September 15, 2008

No. 2106

BUSINESS

- 1 Shionogi to Enter US Market by Acquiring Sciele
- Sciele's Great Growth Potential Justifies Acquisition Cost: Dr Teshirogi
- Aiming at Sales of US\$1 Bil.
- 2 DSP to Design Independent US Marketing System by Mid-2009
- 3 Kowa to Start Independent Marketing of Livalo in the US in 2010
- 4 Novartis Has 8 NDAs Pending: Most Ever
- 4 Jiho-Organized Industry Tour Group Visits Leiden Bio Science Park
- 5 Loxonin Tape Leads Rep Track Survey Ranking in July
- 5 Yamato Will Not Be Able to Be Profitable with Generics Alone: Mr Kumakura
- 8 Will Distribution Practices Be Improved?: Part 1
- 9 Suzuken Expects Price Settlement Rate of Over 70% at the End of September

REGULATORY

- 10 World's 1st Drug for Idiopathic Pulmonary Fibrosis Recommended for Approval
- Sumiferon to Be Approved for Viremia Associated with Hepatic Cirrhosis
- Pediatric Indication to Be Added to Methotrexate
- Max Daily Dose of Cavergoline Reduced
- 12 PMDA Considers New System to Ensure Greater Post-Marketing Safety

- Sodium Phenylbutyrate to Be Designated as Orphan Drug
- 13 NICE to Recommend Lucentis, Not Macugen, to Treat Wet AMD under Health Insurance

R&D

- 13 Otsuka to Codevelop Drug for Dry AMD with Acucela
- Drug for Dry Eye as Well
- 14 VEGF Trap-Eye Improves Vision in Patients with AMD: Bayer, Regeneron
- 14 Pramipexole Improves Symptoms Associated with RLS: BI
- Role of Pramipexole in PD Management Discussed: BI

GENERICS

- 15 Greater Incentives Necessary to Further Increase Use of Generics: Dr Muto
- Systematic Prohibition of Use of Generics the Most Important Problem: Mr Mitsuhara
- 17 *Koroshō* to Verify Quality of Generics of 10 APIs

MEDICAL FACILITIES & NURSING CARE

- 16 A Case of Diagnosis and Treatment of Effort Angina in Japan: Part 2: Diagnosis (CAG)
- 18 AIDS Drugs Effective against Resistant Virus Needed
- 18 Next Generation of Antidiabetic Drugs Discussed: Tokyo Seminar
- 19 Publicity on Effective Migraine Treatment Needed: GSK Seminar
- 19 No Subjective Symptoms in 27% of Glaucoma Patients with Impairment of Half of Visual Field